Initiation of Pilot Clinical Study

Oxford Pharmascience Group plc

("Oxford Pharmascience" or the "Company")

Oxford Pharmascience Announces Initiation of Pilot Clinical Study of OXP001 (Reduced Gastric Irritation Ibuprofen)

Oxford Pharmascience, the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, today announces that dosing of subjects in its pilot clinical study of OXP001 400mg Ibuprofen has begun. OXP001 delivers 400mg of ibuprofen via the company's OXPzero™ technology in a novel salt oral formulation and it aims to provide significantly reduced risks of gastrointestinal (GI) side effects for use in the treatment of conditions requiring the chronic use of Non Steroidal Anti-Inflammatory Drugs (NSAIDs).

The randomised, controlled pilot study - which is being conducted at a single site in the UK - is a two arm study between OXP001 and the reference Ibuprofen 400mg tablets. The purpose of the study is to assess the incidence of upper gastrointestinal irritation via endoscopy using a modified Lanza score. Further details about the study can be found at www.ClinicalTrials.gov.

NSAIDs are one of the most widely used classes of drugs, with more than 30 million users worldwide consuming NSAIDs each day. However, chronic use of NSAIDs causes well documented GI side effects including ulcers and bleeding and leads to significant morbidity and mortality in many patients.

Marcelo Bravo, Chief Executive Officer of Oxford Pharmascience commented:

"The development of GI safer NSAIDs is a key priority for Oxford Pharmascience and it is a great achievement for the Company to have reached this milestone. The study will provide the data that will allow Oxford Pharmascience to proceed with confidence to late Phase III pivotal trials for its reduced gastric irritation ibuprofen product as well as further potential NSAIDs in our pipeline."

For further information:

Oxford Pharmascience Group Plc

Marcelo Bravo, Chief Executive Officer +44 20 7554 5875

N+1 Singer (Nominated Adviser & Broker)

Aubrey Powell/ Jen Boorer +44 20 7496 3000

About Oxford Pharmascience Group Plc

Oxford Pharmascience Group Plc uses a range of proprietary technology platforms to re-develop existing medicines to make them better, safer or easier to take. The Company does not manufacture or sell its own pharmaceutical products direct to consumers, but instead seeks to license its technologies and dossiers to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios.

Oxford Pharmascience Group Plc focuses on existing medicines that are proven to be safe and effective but nevertheless still have associated issues and side effects often affecting compliance. By working with such medicines, the Company is able to develop new innovative products for a fraction of the cost, in much quicker timescales and without the high risk of failure associated with developing new drugs.